BIOMAT Database Logo BIOMAT Database Logo

Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide. 2012

Sunao Yamamoto, and Yosuke Okada, and Hiroko Mori, and Seiji Fukumoto, and Yoshiya Tanaka
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan.

A 44-year-old woman with iron deficiency anemia was on a continuous course of intravenous saccharated ferric oxide (SFO). She came to our hospital because of right hip joint pain. She was found to have hypophosphatemia caused by impaired phosphorus resorption and her fibroblast growth factor 23 (FGF-23) levels were elevated. Therefore, she was diagnosed with FGF-23-related osteomalacia due to SFO administration. Discontinuation of the SFO treatment rapidly improved the impaired phosphorus resorption and also normalized the blood levels of phosphorus and FGF-23. During the treatment with SFO, it is important to regularly measure the blood levels of phosphorus in order to prevent the occurrence of osteomalacia.

UI MeSH Term Description Entries
D010018 Osteomalacia Disorder caused by an interruption of the mineralization of organic bone matrix leading to bone softening, bone pain, and weakness. It is the adult form of rickets resulting from disruption of VITAMIN D; PHOSPHORUS; or CALCIUM homeostasis. Adult Rickets,Rickets, Adult
D010758 Phosphorus A non-metal element that has the atomic symbol P, atomic number 15, and atomic weight 31. It is an essential element that takes part in a broad variety of biochemical reactions. Black Phosphorus,Phosphorus-31,Red Phosphorus,White Phosphorus,Yellow Phosphorus,Phosphorus 31,Phosphorus, Black,Phosphorus, Red,Phosphorus, White,Phosphorus, Yellow
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005290 Ferric Compounds Inorganic or organic compounds containing trivalent iron. Compounds, Ferric
D005346 Fibroblast Growth Factors A family of small polypeptide growth factors that share several common features including a strong affinity for HEPARIN, and a central barrel-shaped core region of 140 amino acids that is highly homologous between family members. Although originally studied as proteins that stimulate the growth of fibroblasts this distinction is no longer a requirement for membership in the fibroblast growth factor family. DNA Synthesis Factor,Fibroblast Growth Factor,Fibroblast Growth Regulatory Factor,Growth Factor, Fibroblast,Growth Factors, Fibroblast
D005937 Glucaric Acid A sugar acid derived from D-glucose in which both the aldehydic carbon atom and the carbon atom bearing the primary hydroxyl group are oxidized to carboxylic acid groups. Glucosaccharic Acid,L-Gularic Acid,Levo-Gularic Acid,Tetrahydroxyadipic Acid,Calcium Glucarate,Calcium Glucarate, Anhydrous,Calcium Saccharate,Calcium Saccharate Anhydrous,Calcium Saccharate Tetrahydrate,Calcium Saccharate, Anhydrous,D-Glucaric Acid,D-Saccharic Acid,Saccharic Acid,Acid, Saccharic,Anhydrous Calcium Glucarate,Anhydrous Calcium Saccharate,D Glucaric Acid,D Saccharic Acid,Glucarate, Anhydrous Calcium,Glucarate, Calcium,L Gularic Acid,Levo Gularic Acid,Saccharate Tetrahydrate, Calcium,Saccharate, Anhydrous Calcium,Saccharate, Calcium,Tetrahydrate, Calcium Saccharate
D006397 Hematinics Agents which improve the quality of the blood, increasing the hemoglobin level and the number of erythrocytes. They are used in the treatment of anemias. Erythropoiesis Stimulating Agent,Hematinic,Hematopoietic Agents,Erythropoiesis Stimulating Agents,Agent, Erythropoiesis Stimulating,Stimulating Agent, Erythropoiesis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077605 Ferric Oxide, Saccharated A glucaric acid-iron conjugate that is used in the treatment of IRON-DEFICIENCY ANEMIA, including in patients with chronic kidney disease, when oral iron therapy is ineffective or impractical. D-Glucaric acid, iron(2+) salt (1:1),Ferri-Saccharate,Ferric Saccharate,Hippiron,Iron Oxide (Saccharated),Iron Sucrose,Iron(III)-Hydroxide Sucrose Complex,Iron-Saccharate,Venofer,Ferri Saccharate,Iron Saccharate,Saccharated Ferric Oxide

Related Publications

Sunao Yamamoto, and Yosuke Okada, and Hiroko Mori, and Seiji Fukumoto, and Yoshiya Tanaka
Iatrogenic osteomalacia caused by intravenous administration of saccharated ferric oxide.
May 1993, American journal of hematology,
Sunao Yamamoto, and Yosuke Okada, and Hiroko Mori, and Seiji Fukumoto, and Yoshiya Tanaka
[Case report; A case of FGF23-related hypophosphatemic osteomalacia caused by long-term administration of saccharated ferric oxide].
October 2011, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Sunao Yamamoto, and Yosuke Okada, and Hiroko Mori, and Seiji Fukumoto, and Yoshiya Tanaka
[Case of osteomalacia due to intravenous saccharated ferric oxide].
July 1998, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Sunao Yamamoto, and Yosuke Okada, and Hiroko Mori, and Seiji Fukumoto, and Yoshiya Tanaka
Acquired Forms of Fibroblast Growth Factor 23-Related Hypophosphatemic Osteomalacia.
April 2024, Endocrinology and metabolism (Seoul, Korea),
Sunao Yamamoto, and Yosuke Okada, and Hiroko Mori, and Seiji Fukumoto, and Yoshiya Tanaka
Sporadic adult-onset hypophosphatemic osteomalacia caused by excessive action of fibroblast growth factor 23.
January 2008, Internal medicine (Tokyo, Japan),
Sunao Yamamoto, and Yosuke Okada, and Hiroko Mori, and Seiji Fukumoto, and Yoshiya Tanaka
[2 cases of nonspecific multiple ulcers of the small intestine associated with osteomalacia caused by long-term intravenous administration of saccharated ferric oxide].
November 1982, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Sunao Yamamoto, and Yosuke Okada, and Hiroko Mori, and Seiji Fukumoto, and Yoshiya Tanaka
Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.
October 2009, Bone,
Sunao Yamamoto, and Yosuke Okada, and Hiroko Mori, and Seiji Fukumoto, and Yoshiya Tanaka
Fibroblast growth factor (FGF)-23 and hypophosphatemic rickets/osteomalacia.
December 2001, Endocrine journal,
Sunao Yamamoto, and Yosuke Okada, and Hiroko Mori, and Seiji Fukumoto, and Yoshiya Tanaka
Saccharated ferric oxide-induced osteomalacia in Japan: iron-induced osteopathy due to nephropathy.
August 1998, Endocrine journal,
Sunao Yamamoto, and Yosuke Okada, and Hiroko Mori, and Seiji Fukumoto, and Yoshiya Tanaka
Osteomalacia induced by a phosphaturic mesenchymal tumor secreting fibroblast growth factor 23.
April 2015, European journal of dermatology : EJD,
Copied contents to your clipboard!